Abbott India LimitedABBOTINDIACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Dec 2025 4 quarters of data

₹26,170.00

MCap ₹55,609 Cr

Abbott India Limited — Stock analysis & AI research Abbott India Limited — Seasonality — best & worst months Abbott India Limited — Technical indicators & charts Abbott India Limited — Technical setup — score, trend, support & resistance Abbott India Limited — Rectangle / Trading Range pattern forming Abbott India Limited — Live exchange announcements

📋 High ROE Stocks 📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 📈 Multi-Timeframe Bearish Stocks 📈 Stocks Near 52-Week Low ⚖️ vs GlaxoSmithKline Pharmaceuticals ⚖️ vs Pfizer 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹1,724 Cr

Sales · Dec 2025

₹463 Cr

Operating Profit · Dec 2025

26.9%

OPM % · Dec 2025

₹376 Cr

Net Profit · Dec 2025

₹176.92

EPS · Dec 2025

📝 Abbott India Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Abbott India Limited reported revenue of ₹1,724 crore for the quarter ended December 2025 (Q3 FY26), and down 1.9% sequentially over the September 2025 quarter.

Net profit stood at ₹376 crore. Earnings per share (EPS) came in at ₹176.92.

Operating profit stood at ₹463 crore — an operating margin (OPM) of 26.9%.

Valuation snapshot

At the current price of ₹26,170.00, ABBOTINDIA has a market capitalisation of ₹55,609 crore.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 13th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 74.99%, foreign institutional investors (FIIs) 0.27%, domestic institutional investors (DIIs) 8.93%, public shareholders 15.81% of Abbott India Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹55,609 Cr

Current Price ?

₹26,170.0

P/E ?

N/A

Industry P/E ?

35.00

P/B ?

11.65

P/S ?

N/A

P/FCF ?

42.55

Enterprise Value ?

₹55,781 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

45.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹1,724 Cr

PAT — latest qtr ?

₹376 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹172 Cr

Debt to Equity ?

0.04

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

74.99%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-6.7%

Return 6 months ?

1.5%

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2024	Mar 2025	Sep 2025	Dec 2025	YoY %	QoQ %
Sales	1,439	1,605	1,757	1,724	—	-1.9%
Operating Profit	330	429	502	463	—	-7.7%
Other Income	81	76	70	70	—	-0.3%
Interest	3	4	8	5	—	-27.4%
Depreciation	18	18	19	19	—	+0.7%
Profit Before Tax	390	483	546	509	—	-6.8%
Net Profit	287	367	415	376	—	-9.5%
EPS	135.09	172.72	195.42	176.92	—	-9.5%
OPM %	22.9%	26.7%	28.6%	26.9%	—	-5.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	21	21	21	21	+0.0%
Reserves	3,167	3,678	4,212	4,753	+12.8%
Borrowings	113	83	197	172	-12.7%
Other Liabilities	1,254	1,411	1,487	1,556	+4.6%
Total Liabilities	4,556	5,193	5,917	6,502	+9.9%
Fixed Assets	237	225	336	331	-1.5%
CWIP	4	10	18	6	-66.7%
Investments	0	0	0	0	—
Other Assets	4,315	4,958	5,563	6,165	+10.8%
Total Assets	4,556	5,193	5,917	6,502	+9.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	893	1,213	1,012	1,319	+30.3%
Cash from Investing Activity	-148	-416	182	-371	-303.8%
Cash from Financing Activity	-639	-745	-925	-1,066	-15.2%
Net Cash Flow	107	52	269	-118	-143.9%
Free Cash Flow	860	1,165	960	1,307	+36.1%
CFO/OP	102%	111%	86%	98%	+14.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	22	20	22	19	-13.6%
Inventory Days	80	70	92	94	+2.2%
Days Payable	109	114	110	109	-0.9%
Cash Conversion Cycle	-8	-24	3	3	+0.0%
Working Capital Days	-8	-14	97	2	-97.9%
ROCE %	41%	46%	46%	45%	-2.2%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	74.99%	74.99%	74.99%	74.99%	+0.0%
FIIs	0.16%	0.16%	0.19%	0.27%	+42.1%
DIIs	9.18%	9.11%	9.00%	8.93%	-0.8%
Public	15.67%	15.74%	15.83%	15.81%	-0.1%
No. of Shareholders	67,584	71,199	75,801	75,866	+0.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUNPHARMA Sun Pharmaceutical	₹1,840.00	441,478	36.5	59,911	12,104	29.8%	20.2%	11.2%	5.1%	10.5%	27.0%
2	DIVISLAB Divi's Laboratories	₹9,235.00	245,160	83.8	11,230	2,925	35.3%	26.0%	12.8%	16.7%	27.8%	65.5%
3	TORNTPHARM Torrent Pharmaceuticals	₹4,931.00	187,559	87.1	15,723	2,156	33.0%	13.7%	21.4%	11.9%	54.8%	3.3%
4	ZYDUSLIFE Zydus Lifesciences	₹1,162.20	115,930	23.2	27,148	5,070	31.2%	18.7%	16.8%	12.0%	16.2%	14.5%
5	CIPLA Cipla	₹1,366.00	110,353	32.7	28,324	3,356	18.7%	11.8%	2.2%	-26.7%	2.3%	-39.2%
6	LAURUSLABS Laurus Labs	₹1,969.00	106,387	97.2	7,270	1,090	28.0%	15.0%	22.7%	147.9%	29.1%	123.9%
7	DRREDDY Dr. Reddy's	₹1,165.50	97,085	29.3	28,704	3,273	15.3%	11.4%	-10.4%	-25.8%	-5.6%	-69.2%
8	AUROPHARMA Aurobindo Pharma	₹1,679.80	96,652	26.2	34,935	3,711	20.3%	10.6%	6.1%	0.6%	16.3%	25.2%
9	LUPIN Lupin	₹2,095.00	95,797	17.9	27,958	5,356	31.5%	19.2%	23.1%	62.0%	31.9%	87.8%
10	MANKIND Mankind Pharma	₹2,280.00	94,174	46.1	14,738	2,067	26.0%	14.0%	16.3%	-3.7%	12.9%	29.1%
11	GLENMARK Glenmark Pharmaceuticals	₹2,419.20	68,276	38.0	17,737	1,797	27.0%	10.1%	-61.2%	-67.4%	23.1%	927.9%
12	ALKEM Alkem Laboratories	₹5,243.50	62,694	29.1	15,081	2,187	20.1%	14.5%	13.5%	7.6%	10.9%	-21.6%
13	ABBOTINDIA Abbott India	₹25,860.00	54,951	34.0	7,005	1,615	28.1%	23.1%	8.1%	9.7%	4.4%	17.2%
14	IPCALAB Ipca Laboratories	₹1,964.20	49,833	38.0	10,125	1,379	22.0%	13.6%	7.9%	55.0%	20.8%	82.2%
15	GLAND Gland Pharma	₹2,935.90	48,433	47.1	6,431	1,028	25.3%	16.0%	-64.7%	-48.4%	22.3%	96.7%
16	AJANTPHARM Ajanta Pharma	₹3,398.90	42,472	37.4	5,777	1,135	25.4%	19.7%	17.3%	14.8%	24.8%	30.9%
17	JBCHEPHARM J. B.	₹2,416.10	38,793	53.4	4,148	709	26.7%	17.1%	5.9%	7.5%	-4.8%	-30.7%
18	EMCURE EMCURE PHARMACEUTICALS	₹1,975.10	37,470	37.0	9,684	1,019	20.4%	10.5%	16.6%	33.1%	22.8%	36.0%
19	WOCKPHARMA Wockhardt	₹2,021.50	32,848	92.5	3,133	353	19.9%	11.3%	-2.3%	342.1%	25.9%	199.1%
20	NEULANDLAB Neuland Laboratories	₹23,455.00	30,093	82.7	2,023	365	28.4%	18.0%	37.0%	40.2%	136.3%	666.0%
21	PPLPHARMA Piramal Pharma	₹211.50	28,024	113.5	9,206	247	11.0%	2.7%	-3.1%	-37.9%	17.4%	-161.3%
22	GRANULES Granules India	₹885.60	21,945	32.8	5,633	663	22.7%	11.8%	19.7%	18.8%	22.0%	59.3%
23	CAPLIPOINT Caplin Point	₹2,752.60	20,923	31.4	2,287	678	34.8%	29.7%	12.9%	20.2%	19.6%	18.8%
24	ERIS Eris Lifesciences	₹1,358.00	18,820	29.0	3,230	666	35.2%	20.6%	8.2%	72.6%	13.0%	14.6%
25	ASTRAZEN AstraZeneca Pharma	₹6,755.00	16,888	99.6	2,432	170	9.4%	7.0%	32.7%	62.1%	29.7%	-32.1%

❓ Frequently asked questions

What was Abbott India Limited's revenue in Q3 FY26?